LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	May '26 May 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '22 Jul 31, 2022
Market Cap	50	41	43	40	-	-
Market Cap Growth	26.52%	-4.75%	8.10%	-	-	-
Enterprise Value	71.3	77.41	62.89	50.91	0	0
Last Close Price	0.41	0.35	0.41	0.49	-	-
PE Ratio	18.07	-17.50	13.67	-4.41	-	-
PS Ratio	1.85	1.43	2.44	3.99	-	-
PB Ratio	1.96	1.53	1.74	4.62	-	-
P/TBV Ratio	1.77	1.53	1.74	4.51	-	-
P/FCF Ratio	-	-9.22	-9.06	-5.17	-	-
P/OCF Ratio	-	-16.84	-26.16	-5.65	-	-
EV/Sales Ratio	2.66	2.69	3.54	5.08	-	-
EV/EBITDA Ratio	17.78	193.04	26.96	-58.52	-	-
EV/EBIT Ratio	50.39	-36.36	76.32	-25.47	-	-
EV/FCF Ratio	-	-17.34	-13.18	-6.59	-	-
Debt / Equity Ratio	1.36	1.36	0.80	1.26	2.68	-
Debt / EBITDA Ratio	95.64	95.64	9.37	-18.70	-1.23	-
Debt / FCF Ratio	-8.59	-8.59	-4.58	-2.11	-3.82	-
Net Debt / Equity Ratio	1.40	1.40	0.87	1.88	3.00	-
Net Debt / EBITDA Ratio	94.27	94.27	9.24	-18.69	-1.23	-
Net Debt / FCF Ratio	-8.47	-8.47	-4.52	-2.10	-3.82	-
Asset Turnover	0.45	0.45	0.42	0.34	0.60	0
Inventory Turnover	2.19	2.19	1.86	2.37	7.02	-
Quick Ratio	0.59	0.59	0.54	0.18	0.11	-
Current Ratio	2.34	2.34	1.59	0.48	0.38	-
Return on Equity (ROE)	-13.35%	-10.87%	19.78%	-121.50%	-315.83%	0.00%
Return on Assets (ROA)	-3.26%	-3.24%	1.92%	-6.87%	-102.01%	0.00%
Return on Invested Capital (ROIC)	-3.60%	-3.59%	2.23%	-8.67%	-132.06%	0.00%
Return on Capital Employed (ROCE)	-3.93%	-3.93%	2.76%	-12.68%	-179.76%	0.00%
Earnings Yield	5.58%	-5.71%	7.32%	-22.68%	-	-
FCF Yield	-	-10.84%	-11.04%	-19.32%	-	-
Buyback Yield / Dilution	-19.11%	-11.58%	-31.13%	-19.66%	-	-
Total Shareholder Return	-19.11%	-11.58%	-31.13%	-19.66%	-	-

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.